Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
Total Valuation
Cartesian Therapeutics has a market cap or net worth of $155.08M. The enterprise value is $43.41M.
Market Cap$155.08M
Enterprise Value$43.41M
Share Statistics
Cartesian Therapeutics has 26,509,024 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding26,509,024
Owned by Insiders41.38%
Owned by Institutions3.50%
Financial Efficiency
Cartesian Therapeutics’s return on equity (ROE) is 1.03 and return on invested capital (ROIC) is -28.36%.
Return on Equity (ROE)1.03
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)-28.36%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee42.38K
Profits Per Employee-1.97M
Employee Count66
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cartesian Therapeutics is ―. Cartesian Therapeutics’s PEG ratio is -0.02.
PE Ratio―
PS Ratio66.95
PB Ratio-1.48
Price to Fair Value-1.48
Price to FCF-2.36
Price to Operating Cash Flow-2.07
PEG Ratio-0.02
Income Statement
In the last 12 months, Cartesian Therapeutics had revenue of 2.80M and earned -130.30M in profits. Earnings per share was -5.02.
Revenue2.80M
Gross Profit2.80M
Operating Income-86.70M
Pretax Income-139.50M
Net Income-130.30M
EBITDA-86.70M
Earnings Per Share (EPS)-5.02
Cash Flow
In the last 12 months, operating cash flow was -73.94M and capital expenditures -5.45M, giving a free cash flow of -79.39M billion.
Operating Cash Flow-73.94M
Free Cash Flow-79.39M
Free Cash Flow per Share-3.00
Dividends & Yields
Cartesian Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.21
52-Week Price Change-53.16%
50-Day Moving Average7.10
200-Day Moving Average8.97
Relative Strength Index (RSI)36.41
Average Volume (3m)246.45K
Important Dates
Cartesian Therapeutics upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 9, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Cartesian Therapeutics as a current ratio of 8.65, with Debt / Equity ratio of -10.04%
Current Ratio8.65
Quick Ratio8.65
Debt to Market Cap0.02
Net Debt to EBITDA1.30
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cartesian Therapeutics has paid -9.19M in taxes.
Income Tax-9.19M
Effective Tax Rate0.07
Enterprise Valuation
Cartesian Therapeutics EV to EBITDA ratio is -0.86, with an EV/FCF ratio of -0.94.
EV to Sales26.74
EV to EBITDA-0.86
EV to Free Cash Flow-0.94
EV to Operating Cash Flow-1.01
Balance Sheet
Cartesian Therapeutics has $125.14M in cash and marketable securities with $12.68M in debt, giving a net cash position of $112.46M billion.
Cash & Marketable Securities$125.14M
Total Debt$12.68M
Net Cash$112.46M
Net Cash Per Share$4.24
Tangible Book Value Per Share-$6.71
Margins
Gross margin is -357.53%, with operating margin of -3099.93%, and net profit margin of -4658.63%.
Gross Margin-357.53%
Operating Margin-3099.93%
Pretax Margin-4987.31%
Net Profit Margin-4658.63%
EBITDA Margin-3099.93%
EBIT Margin-3099.93%
Analyst Forecast
The average price target for Cartesian Therapeutics is $34.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$34.00
Price Target Upside481.20% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast―